Sotorasib (Lumakras®): A Comprehensive Monograph on the First-in-Class KRAS G12C Inhibitor

Executive Summary

Sotorasib represents a landmark achievement in molecular oncology, emerging as the first clinically approved therapeutic agent to successfully target a mutation in the Kirsten rat sarcoma viral oncogene homolog (KRAS), a protein long considered "undruggable." Developed by Amgen under the code name AMG-510 and marketed as Lumakras® or Lumykras®, this small molecule is a highly selective, first-in-class, covalent inhibitor of the specific KRAS p.G12C mutant protein. Its mechanism of action involves irreversibly trapping the mutant protein in an inactive, GDP-bound state, thereby halting the oncogenic signaling cascades that drive tumor proliferation.

This report provides a comprehensive analysis of Sotorasib, synthesizing data on its molecular profile, pharmacology, clinical development, safety, and regulatory status. The initial accelerated approval of Sotorasib for previously treated, locally advanced or metastatic non-small cell lung cancer (NSCLC) was based on the compelling efficacy data from the single-arm CodeBreaK 100 trial. The subsequent confirmatory Phase 3 CodeBreaK 200 trial demonstrated a statistically significant improvement in progression-free survival compared to standard-of-care docetaxel, though without a corresponding benefit in overall survival, a finding complicated by trial design factors such as patient crossover.

In metastatic colorectal cancer (mCRC), Sotorasib monotherapy showed limited activity, revealing tissue-specific resistance mechanisms. However, the pivotal CodeBreaK 300 trial established a new standard of care by demonstrating that Sotorasib in combination with the EGFR inhibitor panitumumab significantly improves outcomes, leading to a new regulatory approval for this indication.

The safety profile of Sotorasib is generally manageable and distinct from traditional chemotherapy, with key adverse events including gastrointestinal effects, musculoskeletal pain, and hepatotoxicity. A notable safety concern is the increased risk of liver toxicity when administered in close sequence with immune checkpoint inhibitors, necessitating careful clinical management. The inevitable emergence of acquired resistance, through both on-target and off-target mechanisms, has defined the next phase of its development. The current and future landscape of Sotorasib is focused on rationally designed combination therapies aimed at overcoming resistance, enhancing efficacy, and moving into earlier lines of treatment, solidifying its role as a foundational agent in the new era of KRAS-targeted cancer therapy.

1. Molecular Profile and Pharmacology

This section establishes the fundamental scientific identity of Sotorasib, detailing its chemical nature, physicochemical properties, and the precise molecular mechanism by which it exerts its targeted therapeutic effect.

1.1. Chemical Identity and Physicochemical Properties

Sotorasib is a synthetic, orally bioavailable small molecule classified as an antineoplastic agent.[1] Its identity is defined by a unique set of chemical and regulatory identifiers essential for scientific and clinical accuracy. The Chemical Abstracts Service (CAS) Registry Number assigned to the active compound is 2252403-56-6.[2] It is crucial to note that this CAS number specifically refers to the active atropisomer of the molecule; AMG-510 can exist in two atropisomeric forms, one of which is more biologically active, highlighting the stereochemical precision integral to its design and function.[4]

The molecular formula of Sotorasib is C30​H30​F2​N6​O3​, corresponding to a monoisotopic mass of 560.2347 g/mol and an average molecular weight of approximately 560.6 g/mol.[1] Chemically, it is a complex pyridopyrimidine derivative, with the full IUPAC name 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-4-pyrido[2,3-d]pyrimidin-2(1H)-one.[1]

In its solid form, Sotorasib appears as an off-white to yellow powder.[6] Its solubility has been characterized in various solvents, which is relevant for both laboratory research and formulation development. It is soluble in DMSO, with limited solubility in water and ethanol.[9] The compound is identified across major drug and chemical databases, including DrugBank (ID: DB15569), PubChem (CID: 137278711), and ChEMBL (ID: CHEMBL4535757).[1]

Sotorasib is developed by Amgen and is known by its code name AMG-510.[1] It is marketed under the brand name Lumakras® in the United States and Lumykras® in the European Union and other regions.[1]

Table 1: Sotorasib Drug Profile Summary

Identifier	Value
Generic Name	Sotorasib
Brand Names	Lumakras® (US), Lumykras® (EU) 1
Code Name	AMG-510 1
Drug Type	Small Molecule, Synthetic Organic 1
DrugBank ID	DB15569 1
CAS Number	2252403-56-6 (Active Atropisomer) 2
Molecular Formula	C30​H30​F2​N6​O3​ 2
Molecular Weight	560.6 g/mol (Average) 1
IUPAC Name	6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-pyrido[2,3-d]pyrimidin-2-one 10

1.2. Mechanism of Action: Covalent Inhibition of the KRAS G12C Mutant

Sotorasib's therapeutic effect is rooted in its highly specific and irreversible inhibition of the KRAS G12C mutant protein, a molecular target that was for decades considered intractable.[3] The KRAS protein is a small guanosine triphosphatase (GTPase) that functions as a critical molecular switch in intracellular signaling. It cycles between an active, guanosine triphosphate (GTP)-bound state and an inactive, guanosine diphosphate (GDP)-bound state. In its active form, KRAS engages downstream effector proteins, such as RAF and PI3K, to propagate signals along pathways like the mitogen-activated protein kinase (MAPK) cascade, which governs fundamental cellular processes including proliferation, differentiation, and survival.[3]

The KRAS p.G12C mutation involves a single amino acid substitution of glycine with cysteine at codon 12 of the protein. This specific alteration impairs the intrinsic GTPase activity of the KRAS protein, which is responsible for hydrolyzing GTP to GDP. As a result, the mutant protein becomes trapped in its constitutively active, GTP-bound "on" state, leading to hyperactivation of downstream pathways and uncontrolled cell growth, a hallmark of cancer.[3] The G12C mutation is present in approximately 13% of NSCLC adenocarcinomas and 3-5% of colorectal and appendix cancers.[1]

Sotorasib was ingeniously designed to exploit the unique chemical properties of this mutant cysteine residue. The drug contains an acrylamide "warhead" that enables it to form a specific and irreversible covalent bond with the thiol group of the cysteine-12 residue.[3] This interaction occurs within a cryptic pocket of the KRAS protein known as the switch-II region, which is accessible only when the protein is in its inactive, GDP-bound "off" state.[3] By covalently binding to this site, Sotorasib effectively locks the KRAS G12C protein in this inactive conformation, preventing it from cycling back to the active GTP-bound state and thereby blocking its oncogenic signaling output.[8]

1.3. Pharmacodynamics and Target Selectivity

A key feature of Sotorasib's design is its remarkable selectivity for the KRAS G12C mutant over the wild-type (non-mutated) KRAS protein. This specificity is conferred by its mechanism of action, as the wild-type KRAS protein lacks the targetable cysteine residue at codon 12. This prevents off-target inhibition of normal KRAS function in healthy cells, which is a critical factor contributing to the drug's manageable safety profile.[1]

In vitro studies have confirmed this selectivity, demonstrating that Sotorasib exerts a potent, concentration-dependent anti-proliferative effect specifically on colon cancer cell lines engineered to express the KRAS G12C mutation, while having no effect on wild-type cells.[4]

Beyond its direct cytotoxic effect on tumor cells, Sotorasib also exhibits important immunomodulatory properties. Preclinical studies conducted in immune-competent mouse models revealed that treatment with Sotorasib not only led to tumor regression but also induced a pro-inflammatory tumor microenvironment.[4] This transformation is characterized by an influx of immune cells, such as T cells, which are capable of recognizing and attacking cancer cells. This effect was so profound that Sotorasib treatment alone produced durable cures in some models. Furthermore, mice that were cured of their KRAS G12C tumors were able to reject subsequent challenges with tumors expressing a different KRAS mutation (G12D), suggesting the development of a broad adaptive immune memory against shared tumor antigens.[4]

This dual mechanism of action—direct inhibition of oncogenic signaling and simultaneous enhancement of anti-tumor immunity—is a significant finding. It suggests that Sotorasib does not merely halt tumor growth but also renders the tumor more susceptible to immune-mediated destruction. This provides a strong biological rationale for combining Sotorasib with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 antibodies), a strategy that is being actively explored in clinical trials. The potential for synergy is high, as Sotorasib could convert immunologically "cold" tumors, which are typically resistant to immunotherapy, into "hot" tumors that are responsive to immune attack.

1.4. Clinical Pharmacokinetics and Metabolism

The pharmacokinetic profile of Sotorasib has been well-characterized through studies in both healthy volunteers and cancer patients, defining its absorption, distribution, metabolism, and excretion (ADME) properties.

• Absorption: Sotorasib is administered orally. Following a standard 960 mg once-daily dose, the drug is absorbed, reaching a peak plasma concentration (Cmax​) of 7.50 µg/mL. The median time to reach this peak concentration (Tmax​) is 2.0 hours. The total drug exposure over a 24-hour period, measured as the area under the curve (AUC0−24h​), is 65.3 h·µg/mL.[1]
• Distribution: Once in the bloodstream, Sotorasib distributes widely throughout the body, as indicated by a large apparent volume of distribution (Vd​) of 211 L. It is also highly bound (89%) to plasma proteins, which can influence its distribution and availability to target tissues.[1]
• Metabolism: Sotorasib is primarily metabolized in the liver. The main metabolic pathways are conjugation and oxidation mediated by the cytochrome P450 3A (CYP3A) family of enzymes.[1]
• Excretion: The primary route of elimination is through the feces, which accounts for 74% of the administered dose. A much smaller fraction (6%) is eliminated in the urine. A substantial portion of the drug is excreted unmetabolized, with 53% of the total dose recovered as the unchanged parent compound in the feces.[1] Sotorasib has a terminal elimination half-life ( t1/2​) of 5.5 hours and an apparent clearance at steady state of 26.2 L/h.[1]

The drug's reliance on CYP3A enzymes for metabolism and its sensitivity to gastric pH create a high potential for clinically significant drug-drug interactions. Extensive Phase 1 studies in healthy volunteers were conducted to characterize these risks.[16] Co-administration with strong inhibitors of CYP3A4, such as the antifungal agent itraconazole, can increase Sotorasib plasma concentrations, potentially leading to increased toxicity. Conversely, co-administration with strong CYP3A4 inducers, such as the antibiotic rifampin, can significantly decrease Sotorasib concentrations, risking a loss of efficacy.

Furthermore, Sotorasib's absorption is affected by gastric pH. Acid-reducing agents, such as proton pump inhibitors (e.g., omeprazole) and H2-receptor antagonists (e.g., famotidine), can decrease its solubility and absorption.[16] This interaction is of high clinical relevance, as these medications are frequently used by cancer patients. This necessitates careful medication management and specific administration guidelines to avoid compromising the drug's therapeutic effect. Sotorasib itself can also act as an inducer of CYP3A4 and an inhibitor of transporters like P-glycoprotein, affecting the pharmacokinetics of other co-administered drugs like rosuvastatin, digoxin, and metformin.[1] These complex interactions underscore the need for thorough medication review by clinicians and pharmacists when initiating Sotorasib therapy.

Table 2: Summary of Sotorasib Pharmacokinetic Parameters

Parameter	Value
Tmax​ (Time to Peak Concentration)	2.0 hours (median)
Cmax​ (Peak Plasma Concentration)	7.50 µg/mL
AUC0−24h​ (Area Under the Curve)	65.3 h·µg/mL
Volume of Distribution (Vd​)	211 L
Plasma Protein Binding	89%
Terminal Elimination Half-life (t1/2​)	5.5 ± 1.8 hours
Apparent Clearance	26.2 L/h
(Data from a 960 mg once-daily dose) 1

2. Clinical Development and Efficacy in Non-Small Cell Lung Cancer (NSCLC)

The clinical development program for Sotorasib, named CodeBreaK, has been instrumental in establishing its role as a targeted therapy for patients with KRAS G12C-mutated NSCLC. This section details the pivotal trials that provided the evidence for its regulatory approval and defined its clinical utility in this setting.

2.1. The CodeBreaK 100 Trial: Foundational Evidence in Pre-treated NSCLC

The CodeBreaK 100 study (NCT03600883) was a multicenter, single-arm, open-label Phase 1/2 trial that served as the cornerstone for Sotorasib's initial approval.[17] The Phase 2 portion of the trial was particularly significant, enrolling 126 patients with locally advanced or metastatic NSCLC whose tumors harbored the KRAS G12C mutation and who had experienced disease progression after prior systemic therapies, including platinum-based chemotherapy and/or immune checkpoint inhibitors.[17]

The results from this heavily pre-treated population were highly encouraging and represented a major advance for a patient group with historically poor outcomes.[20] The trial demonstrated an objective response rate (ORR), the primary endpoint, of 37.1%, as assessed by blinded independent central review. This included four complete responses and 42 partial responses.[20] The responses were not only frequent but also rapid and durable. The median duration of response (DoR) was 11.1 months, indicating that patients who responded to the therapy maintained that benefit for a substantial period.[20]

Key secondary endpoints further supported the drug's clinical benefit. The disease control rate (DCR), which includes patients with stable disease in addition to those with a response, was 80.6%.[20] The median progression-free survival (PFS) was 6.8 months, and the median overall survival (OS) was 12.5 months.[20] A 2-year analysis of the combined Phase 1 and 2 cohorts (174 patients) confirmed these long-term benefits, showing an ORR of 41%, a median DoR of 12.3 months, and a 2-year OS rate of 33%.[24] Based on the strength of these data, the U.S. Food and Drug Administration (FDA) granted Sotorasib accelerated approval on May 28, 2021, for this patient population.[1]

2.2. The CodeBreaK 200 Trial: A Phase 3 Comparison with Docetaxel

As a condition of its accelerated approval, a confirmatory trial was required to verify Sotorasib's clinical benefit. This led to the CodeBreaK 200 trial (NCT04303780), a global, randomized, open-label Phase 3 study designed to compare the efficacy and safety of Sotorasib with the standard-of-care second-line chemotherapy, docetaxel.[18] The trial enrolled 345 patients with pre-treated KRAS G12C-mutated NSCLC, randomizing them on a 1:1 basis to receive either oral Sotorasib (960 mg once daily) or intravenous docetaxel.[27]

The trial successfully met its primary endpoint, demonstrating a statistically significant improvement in PFS for Sotorasib over docetaxel.[28] At a median follow-up of 17.7 months, the median PFS was 5.6 months in the Sotorasib arm compared to 4.5 months in the docetaxel arm, corresponding to a 34% reduction in the risk of disease progression or death (Hazard Ratio = 0.66; 95% CI, 0.51–0.86; p=0.0017).[28] The benefit was more pronounced at the 12-month mark, with a PFS rate of 24.8% for Sotorasib versus just 10.1% for docetaxel, effectively more than doubling the proportion of patients who remained progression-free at one year.[28]

Secondary efficacy endpoints also favored Sotorasib. The ORR was more than double that of chemotherapy (28.1% vs. 13.2%; p<0.001), and the DCR was also significantly higher (82.5% vs. 60.3%).[28] However, the trial did not demonstrate a statistically significant improvement in the key secondary endpoint of overall survival. The median OS was 10.6 months for Sotorasib compared to 11.3 months for docetaxel (HR = 1.01).[28] Sotorasib did show a more favorable safety profile, with fewer Grade ≥3 TRAEs (33% vs. 40%) and substantially fewer serious TRAEs (11% vs. 23%) compared to docetaxel.[28]

2.3. Efficacy Across Key NSCLC Subgroups and the Nuanced Interpretation of Survival Data

Exploratory analyses from both the CodeBreaK 100 and 200 trials demonstrated that the clinical benefit of Sotorasib was consistent across various clinically relevant patient subgroups.[22] This included patients with different baseline levels of PD-L1 expression and, notably, those with co-occurring mutations in genes such as

STK11, KEAP1, and TP53, which are often associated with poor prognosis.[20] This consistency across subgroups reinforces the robustness of Sotorasib's activity against its specific molecular target.

The lack of an overall survival benefit in the CodeBreaK 200 trial, despite clear advantages in PFS, ORR, and safety, sparked considerable debate and requires a nuanced interpretation. A critical factor confounding the OS result was the trial's design, which permitted patients in the docetaxel arm to cross over and receive a KRAS G12C inhibitor after their disease progressed.[28] Data show that 34% of patients in the docetaxel arm subsequently received a KRAS G12C inhibitor, including 26% who crossed over to Sotorasib within the trial.[28] This crossover effectively provides the control arm with access to the more effective targeted therapy later in their treatment course, which can dilute or even erase any observable difference in overall survival between the two arms.

Therefore, the OS data from this trial do not necessarily reflect a lack of survival benefit for Sotorasib but rather the benefit of having a KRAS G12C inhibitor available at any point in the treatment paradigm. The true clinical value of Sotorasib in this setting is more holistically captured by its other demonstrated advantages. It provides a significant delay in disease progression (PFS benefit), a higher likelihood of tumor shrinkage (ORR benefit), and a superior safety profile. Furthermore, patient-reported outcomes from CodeBreaK 200 strongly favored Sotorasib, showing a significant delay in the time to deterioration of global health status, physical functioning, and key cancer-related symptoms like cough and dyspnea.[30] The convenience of an oral, once-daily therapy compared to intravenous chemotherapy also represents a significant improvement in quality of life.

Despite these points, the FDA's Oncologic Drugs Advisory Committee voted that the trial's benefit could not be reliably interpreted due to potential biases, and the agency ultimately issued a complete response letter for the full approval application in December 2023. A new post-marketing requirement for an additional confirmatory study was issued, with a completion deadline of February 2028, leaving the NSCLC indication under accelerated approval status in the U.S..[15]

3. Clinical Efficacy in Metastatic Colorectal Cancer (mCRC) and Other Solid Tumors

While Sotorasib's initial success was in NSCLC, its development in other KRAS G12C-mutated tumors, particularly mCRC, has revealed important biological insights and highlighted the necessity of combination strategies to achieve meaningful clinical benefit.

3.1. The CodeBreaK 300 Trial: Establishing a New Standard of Care with Panitumumab

Early data from the CodeBreaK 100 trial showed that Sotorasib as a monotherapy had limited activity in patients with mCRC, with an ORR of only around 12%.[34] This was in stark contrast to the efficacy observed in NSCLC and pointed toward intrinsic resistance mechanisms within colorectal tumors. Preclinical evidence suggested that feedback reactivation of the epidermal growth factor receptor (EGFR) signaling pathway was a primary escape mechanism. When KRAS G12C is inhibited, tumor cells can compensate by upregulating EGFR signaling to reactivate the downstream MAPK pathway.

This biological rationale led to the design of the pivotal Phase 3 CodeBreaK 300 trial (NCT05198934).[15] This randomized, open-label study evaluated Sotorasib in combination with panitumumab (Vectibix®), a monoclonal antibody that blocks the EGFR, in patients with chemorefractory KRAS G12C-mutated mCRC. The trial enrolled 160 patients who had previously received standard fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.[15] The combination therapy was compared against the investigator's choice of standard care, which consisted of either trifluridine/tipiracil or regorafenib.[35]

The results were practice-changing. The combination of Sotorasib (at the 960 mg dose) plus panitumumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival. The median PFS was 5.6 months for the combination arm, compared to just 2.2 months for the standard care arm. This represented a 51% reduction in the risk of disease progression or death (HR = 0.49; 95% CI, 0.30-0.80; p=0.006).[36] The ORR was 26.4% for the combination, whereas no patients in the standard care arm achieved an objective response.[36] These robust findings validated the EGFR-feedback hypothesis and established Sotorasib plus panitumumab as the first and only targeted treatment combination for this patient population.[15] Based on these results, the FDA approved the combination for this indication on January 16, 2025.[15]

3.2. Dose Optimization and Efficacy in mCRC

A unique and important feature of the CodeBreaK 300 trial was the inclusion of two different Sotorasib dose levels: the standard 960 mg once daily and a lower 240 mg once daily dose, both in combination with panitumumab.[15] This design allowed for a direct comparison to determine the optimal dose in the mCRC setting.

The data conclusively showed the superiority of the higher dose. The ORR for the 960 mg arm was 26.4%, compared to just 5.7% for the 240 mg arm.[36] The median PFS was also longer with the 960 mg dose (5.6 months vs. 3.9 months).[36] The final analysis of overall survival, although the trial was not powered for this endpoint, showed a strong trend favoring the 960 mg dose. Median OS was not reached in the 960 mg arm, compared to 11.9 months in the 240 mg arm and 10.3 months in the standard care arm (HR for 960 mg vs. standard care = 0.70).[39] These findings firmly established 960 mg once daily as the recommended dose of Sotorasib for use in combination with panitumumab for mCRC.[37]

The contrasting efficacy of Sotorasib monotherapy in NSCLC versus mCRC provides a crucial lesson in targeted therapy: the genetic context of the tumor's tissue of origin is a critical determinant of therapeutic strategy. While the KRAS G12C mutation is the primary driver in both cancers, colorectal tumors appear to have a much stronger innate reliance on parallel signaling pathways, particularly EGFR, which allows them to rapidly adapt and escape the effects of KRAS inhibition alone. Unlocking the therapeutic potential of Sotorasib in mCRC required a rational combination approach that simultaneously blocked both the primary driver and the key escape route. This principle underscores the importance of tailoring combination strategies not just to the specific driver mutation but also to the unique biological dependencies of each cancer type.

3.3. Investigational Use in Other KRAS G12C-Mutated Malignancies

The KRAS G12C mutation, while most common in lung adenocarcinoma, is also found at lower frequencies (1-3%) across a wide range of other solid tumors, including pancreatic, appendix, and other cancers.[1] The broad clinical development program for Sotorasib includes the CodeBreaK 101 study (NCT04185883), a multi-arm "basket" trial designed to evaluate Sotorasib both as a monotherapy and in various combinations across different KRAS G12C-mutated solid tumors.[42]

However, progress in other tumor types has been challenging. For example, a Phase 1/2 trial (NCT05251038) evaluating Sotorasib combined with standard chemotherapy (gemcitabine and nab-paclitaxel) for the second-line treatment of pancreatic cancer was withdrawn before completion, highlighting the significant difficulties in treating this particularly aggressive malignancy.[44] These experiences further reinforce the notion that effective strategies will likely require highly tailored, tumor-specific combination approaches.

Table 3: Summary of Efficacy Outcomes from Pivotal CodeBreaK Trials

Trial	Tumor Type	Treatment Arm(s)	ORR (95% CI)	DCR (95% CI)	Median DoR (months)	Median PFS (months)	Median OS (months)
CodeBreaK 100 (Ph 2) 20	NSCLC	Sotorasib 960 mg	37.1% (28-45)	80.6%	11.1	6.8	12.5
CodeBreaK 200 (Ph 3) 28	NSCLC	Sotorasib 960 mg	28.1% (21.5-35.4)	82.5%	8.6	5.6	10.6
		Docetaxel	13.2% (8.6-19.2)	60.3%	6.8	4.5	11.3
CodeBreaK 300 (Ph 3) 36	mCRC	Sotorasib 960 mg + Panitumumab	26.4% (15.3-40.3)	71.7%	4.4	5.6	Not Reached
		Standard of Care	0% (0.0-6.6)	46.3%	N/A	2.2	10.3

4. Comprehensive Safety, Tolerability, and Risk Management

A thorough understanding of a drug's safety profile is essential for its appropriate clinical use. This section synthesizes the safety and tolerability data for Sotorasib from its clinical development program, focusing on common adverse events, serious risks, and strategies for their management.

4.1. Analysis of the Integrated Safety Profile

Across the CodeBreaK clinical trial program, Sotorasib has demonstrated a manageable safety profile that is distinct from that of traditional chemotherapy. The most frequently reported treatment-related adverse reactions (TRAEs), occurring in ≥20% of patients receiving Sotorasib monotherapy, include diarrhea, musculoskeletal pain, nausea, fatigue, hepatotoxicity (manifesting as elevated liver enzymes), and cough.[3] The majority of these events are mild to moderate in severity (Grade 1 or 2).[29]

In the randomized CodeBreaK 200 trial, Sotorasib was better tolerated than docetaxel. The incidence of Grade ≥3 TRAEs was lower in the Sotorasib arm (33%) compared to the docetaxel arm (40%). Furthermore, serious TRAEs were reported in less than half as many patients receiving Sotorasib (11%) as in those receiving docetaxel (23%).[28]

When used in combination with panitumumab for mCRC in the CodeBreaK 300 trial, the safety profile reflected the toxicities of both agents. The most common TRAEs were dermatologic toxicities (e.g., rash, dermatitis acneiform) and hypomagnesemia, which are well-known side effects of the EGFR inhibitor panitumumab.[35] The incidence of Grade ≥3 TRAEs in the 960 mg Sotorasib plus panitumumab arm was 35.8%, comparable to the 43.1% seen in the standard chemotherapy arm.[36]

4.2. Management of Key Adverse Reactions: Hepatotoxicity and ILD/Pneumonitis

While generally manageable, Sotorasib is associated with two key serious adverse reactions that require vigilant monitoring and specific management protocols: hepatotoxicity and interstitial lung disease (ILD)/pneumonitis.

• Hepatotoxicity: Elevation of liver transaminases (alanine aminotransferase and aspartate aminotransferase) is a common and important adverse event associated with Sotorasib.[17] Clinical guidelines mandate that liver function tests be performed at baseline before starting treatment and then monitored regularly throughout therapy.[46] If significant elevations occur, management involves withholding the drug, reducing the dose upon recovery, or, in severe cases, permanently discontinuing treatment. Corticosteroids may also be used in some cases of hepatotoxicity.[15]

A critical factor influencing the risk of hepatotoxicity is the timing of Sotorasib administration relative to prior immunotherapy. A pooled safety analysis revealed a stark difference: 40% of NSCLC patients who started Sotorasib within 3 months of their last immunotherapy dose developed hepatotoxicity. In contrast, the incidence was only 17-18% in patients who had not received recent immunotherapy.[15] This suggests a potential for synergistic immune-mediated liver injury and has significant implications for clinical practice. Clinicians must carefully consider a patient's recent treatment history, and a "washout" period after immunotherapy may be prudent to mitigate this heightened risk. This finding also complicates the development of concurrent Sotorasib and immunotherapy combinations, which, though promising for efficacy, may be limited by this toxicity.

• Interstitial Lung Disease (ILD)/Pneumonitis: This is a less common but potentially fatal adverse reaction characterized by inflammation of the lungs.[17] A fatal case of ILD was reported in the Sotorasib arm of the CodeBreaK 200 trial.[28] Patients must be monitored closely for any new or worsening respiratory symptoms, such as shortness of breath, cough, or fever. If ILD/pneumonitis is suspected, Sotorasib must be immediately withheld. If the diagnosis is confirmed, the drug should be permanently discontinued.[45]

4.3. Significant Drug-Drug Interactions and Co-administration Guidelines

Sotorasib's pharmacokinetic profile predisposes it to several clinically significant drug-drug interactions that require careful management.

• Acid-Reducing Agents: The absorption of Sotorasib is pH-dependent. Co-administration with drugs that increase gastric pH, such as proton pump inhibitors (PPIs, e.g., omeprazole) and H2-receptor antagonists (e.g., famotidine), can significantly decrease Sotorasib's plasma concentration and should be avoided.[48] If a locally-acting antacid is required, it must be administered on a staggered schedule: Sotorasib should be taken at least 4 hours before or 10 hours after the antacid dose.[12]
• CYP3A4 Modulators: As Sotorasib is a substrate of the CYP3A4 enzyme, its plasma levels are sensitive to co-administered drugs that inhibit or induce this pathway. Strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, clarithromycin) can increase Sotorasib exposure and the risk of toxicity. Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John's Wort) can decrease Sotorasib exposure and compromise its efficacy. Concomitant use with strong inducers or inhibitors should be avoided.[1]
• P-gp and CYP3A4 Substrates: Sotorasib can act as an inducer of CYP3A4 and an inhibitor of the P-glycoprotein (P-gp) efflux transporter. This means it can decrease the plasma concentrations of drugs that are sensitive CYP3A4 substrates (e.g., alfentanil, midazolam) or P-gp substrates (e.g., digoxin, dabigatran). Careful monitoring or dose adjustments of these concomitant medications may be necessary.[1]

Table 4: Incidence of Common Treatment-Related Adverse Events (TRAEs)

Adverse Event	CodeBreaK 100 (NSCLC, Sotorasib Mono) 20	CodeBreaK 200 (NSCLC, Sotorasib Mono) 28	CodeBreaK 300 (mCRC, Soto + Pani) 35
	All Grades (%)	Grade ≥3 (%)	Grade ≥3 (%)
Diarrhea	42	5	12
Musculoskeletal Pain	35	8	-
Nausea	26	1	-
Fatigue	26	2	-
Hepatotoxicity (ALT/AST ↑)	18	6	8 (ALT), 5 (AST)
Cough	20	1.5	-
Rash/Dermatitis	-	-	-
Dry Skin	-	-	-
Stomatitis	-	-	-

Table 5: Dose Modification Guidelines for Key Toxicities

Adverse Reaction	Severity (Grade)	Recommended Action
Hepatotoxicity (ALT/AST ↑)	Grade 2	Withhold until ≤ Grade 1, then resume at same or reduced dose.
	Grade 3 or 4	Withhold until ≤ Grade 1, then resume at reduced dose. Permanently discontinue if recurs at Grade ≥3.
ILD/Pneumonitis	Any Grade	Withhold if suspected. Permanently discontinue if confirmed.
Nausea or Vomiting	Grade 3 or 4	Withhold until ≤ Grade 1, then resume at next lower dose level.
Diarrhea	Grade 3 or 4	Withhold until ≤ Grade 1, then resume at next lower dose level.
(Source: 45)

5. Regulatory Status, Dosing, and Administration

This section outlines the regulatory journey of Sotorasib, detailing its approvals by major health authorities, and provides practical guidance on patient selection, dosing, and administration for clinical practice.

5.1. Global Regulatory Approvals and Post-Marketing Commitments

Sotorasib's journey to market has been rapid, facilitated by regulatory pathways designed for drugs addressing high unmet medical needs.

• United States (FDA): The U.S. Food and Drug Administration granted Sotorasib accelerated approval on May 28, 2021, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic therapy.[1] This initial approval was based on the promising ORR and DoR data from the CodeBreaK 100 trial. Following the results of the CodeBreaK 200 confirmatory trial, the FDA issued a complete response letter for the full approval application in December 2023 and mandated a new confirmatory study, to be completed by February 2028.[15] Subsequently, on January 16, 2025, the FDA granted full approval for Sotorasib in combination with panitumumab for adult patients with KRAS G12C-mutated mCRC who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, based on the CodeBreaK 300 trial results.[15]
• European Union (EMA): The European Commission, following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), granted conditional marketing authorization for Sotorasib on January 6, 2022.[50] The indication is for the treatment of adults with advanced NSCLC with a KRAS G12C mutation who have progressed after at least one prior systemic therapy.[52]
• Other Regions: Sotorasib has received regulatory approval in over 35 countries worldwide. This has been facilitated in part by initiatives like the FDA's Project Orbis, which allows for concurrent submission and review of oncology products among international partners, including regulatory agencies in Canada, the United Kingdom, Australia, and Brazil.[53]

5.2. Patient Selection, Dosing Regimen, and Administration Protocols

The appropriate use of Sotorasib in the clinic depends on correct patient selection, adherence to the recommended dosing regimen, and proper administration.

• Patient Selection: Treatment with Sotorasib is strictly indicated for patients whose tumors have a confirmed KRAS G12C mutation. This must be determined by a validated, FDA-approved diagnostic test.[17] For NSCLC, the mutation can be detected in either tumor tissue or circulating tumor DNA (ctDNA) from a plasma specimen. If a plasma test is negative, tumor tissue should be tested to confirm the absence of the mutation.[19] For mCRC, selection is based on the presence of the mutation in a tumor specimen.[48]
• Standard Dosing Regimen: The recommended dose of Sotorasib is 960 mg taken orally once daily.[3] This dose is used for both NSCLC monotherapy and in combination with panitumumab for mCRC. Treatment should continue until disease progression or unacceptable toxicity.[17] The 960 mg dose can be taken with or without food.[55]
• Dosage Forms: Sotorasib is available in multiple tablet strengths to accommodate the daily dose: 120 mg (yellow), 240 mg (yellow), and 320 mg (beige) tablets.[12]
• Administration Protocols:
• Patients should take their dose at approximately the same time each day.[55]
• Tablets should be swallowed whole and should not be chewed, crushed, or split.[49]
• For patients who have difficulty swallowing tablets, the daily dose may be dispersed in 120 mL (4 ounces) of non-carbonated, room-temperature water. The tablets should not be crushed. The mixture should be stirred until the tablets break into small pieces (they will not dissolve completely) and consumed immediately or within 2 hours. The glass should then be rinsed with an additional 120 mL of water, which should also be consumed to ensure the full dose is taken.[12]
• Dose Modifications for Adverse Reactions: If adverse reactions occur, the dose of Sotorasib can be reduced. The first dose reduction is to 480 mg once daily. The second dose reduction is to 240 mg once daily. If a patient is unable to tolerate the 240 mg daily dose, Sotorasib should be permanently discontinued.[48]
• Missed Dose or Vomiting: If a dose is missed by more than 6 hours, the patient should skip that dose and take the next dose at the regularly scheduled time. Patients should not take two doses to make up for a missed one. If a patient vomits after taking a dose, they should not take an additional dose but should take the next dose as scheduled.[12]

6. The Evolving Landscape of KRAS G12C Inhibition

Sotorasib's approval marked the beginning, not the end, of a new chapter in oncology. The field is now rapidly evolving, driven by the challenges of drug resistance, the emergence of competitors, and the pursuit of more effective therapeutic strategies.

6.1. Acquired Resistance: On-Target and Off-Target Mechanisms

As with most targeted therapies, the durable efficacy of Sotorasib is limited by the eventual development of acquired resistance.[56] Clinical and preclinical studies have identified a heterogeneous array of resistance mechanisms, which can be broadly classified into two categories:

• On-Target Resistance: These mechanisms involve alterations to the KRAS G12C protein itself or its direct regulation, which either prevent Sotorasib from binding or overcome its inhibitory effect. Examples include:
• Secondary KRAS Mutations: New mutations can arise in the KRAS gene that alter the drug's binding site (e.g., Y96D, R68S, H95D/Q/R) or confer resistance through other means (e.g., G13D, A59S).[56]
• KRAS G12C Allele Amplification: The cancer cell can make multiple copies of the KRAS G12C gene, increasing the amount of the target protein to a level that overwhelms the inhibitory capacity of the drug.[56]
• Off-Target Resistance: These mechanisms involve the activation of alternative signaling pathways that bypass the need for KRAS G12C signaling, effectively creating a detour around the therapeutic blockade. This is the more common mode of resistance. Examples include:
• Receptor Tyrosine Kinase (RTK) Pathway Activation: This is the most prevalent pathway of resistance. It can involve the amplification or mutation of various RTKs, such as MET, EGFR, or FGFR3, which can then reactivate the MAPK pathway downstream of KRAS.[34]
• Bypass Mutations: Activating mutations can occur in other genes within the MAPK pathway (e.g., NRAS, BRAF, MEK) or parallel pathways like the PI3K pathway (PI3KCA).[56]
• Non-Genomic Mechanisms: Resistance can also arise without new genetic alterations. Histological transdifferentiation, where a lung adenocarcinoma transforms into a squamous cell carcinoma, has been observed.[56] Epithelial-to-mesenchymal transition (EMT) is another cellular process that can confer resistance to Sotorasib.[56]

The diversity of these escape routes highlights the complexity of overcoming resistance and strongly suggests that combination therapies targeting multiple nodes in these signaling networks will be essential for achieving more durable responses.

6.2. The Competitive Context: Sotorasib versus Adagrasib

Sotorasib is not the only approved KRAS G12C inhibitor. Adagrasib (Krazati®), developed by Mirati Therapeutics, received FDA approval shortly after Sotorasib, creating a competitive landscape. As there are no head-to-head clinical trials comparing the two drugs, their relative merits are assessed through single-arm trial data and statistical methods like matching-adjusted indirect comparisons (MAIC).[60]

An MAIC analysis comparing data from the CodeBreaK 200 (Sotorasib) and KRYSTAL-12 (Adagrasib) Phase 3 trials suggests that the two drugs have comparable overall efficacy in previously treated NSCLC. The analysis found no statistically significant difference in PFS (HR 0.93) or ORR (odds ratio 0.86).[60] However, this analysis did reveal potentially important differences in their safety profiles and activity in specific patient populations. Sotorasib was associated with a more favorable safety profile, showing lower odds of TRAEs overall, as well as TRAEs leading to dose reduction or interruption.[60]

Conversely, some evidence suggests that adagrasib may have superior activity in patients with central nervous system (CNS) metastases, a common and challenging clinical scenario in NSCLC.[62] The MAIC analysis found that among patients with baseline brain metastases, Sotorasib was associated with a 39% reduced risk of progression compared to adagrasib.[60] The hepatotoxicity profiles may also differ, particularly concerning the interaction with prior immunotherapy, though this requires further study.[65]

This creates a clinical environment defined by nuance rather than clear dominance. The choice between Sotorasib and Adagrasib is not straightforward and may depend on individual patient characteristics. A patient with significant CNS disease might be a candidate for Adagrasib, whereas a patient with a higher baseline risk for toxicity or who has recently completed immunotherapy might be better suited for Sotorasib. This nuanced landscape will likely allow both drugs to occupy distinct clinical niches while driving the development of next-generation inhibitors that aim to improve upon both efficacy and safety.

6.3. Future Directions: Combination Strategies and Next-Generation Inhibitors

The future of KRAS G12C inhibition is focused on two primary strategies: optimizing the use of existing inhibitors through combination therapies and developing novel inhibitors with improved properties or broader targets.

• Combination Strategies: The vast majority of ongoing research with Sotorasib involves combination therapy. The goal is to overcome or delay resistance, improve the depth and durability of response, and move Sotorasib into earlier lines of treatment.
• The CodeBreaK 101 trial is a large, multi-arm platform study evaluating Sotorasib in combination with a wide array of agents, including other targeted therapies (SHP2 inhibitors, SOS1 inhibitors), chemotherapy (platinum doublets), and immunotherapy.[43] Early results from the chemotherapy combination in first-line NSCLC are promising, showing an ORR of 65% and a median PFS of 10.8 months.[67]
• The CodeBreaK 202 trial (NCT05920356) is a Phase 3 study directly challenging the current standard of care in the first-line setting. It is comparing Sotorasib plus platinum doublet chemotherapy against pembrolizumab (an immune checkpoint inhibitor) plus platinum doublet chemotherapy in patients with PD-L1 negative, KRAS G12C-mutated advanced NSCLC.[68]
• Other trials are exploring Sotorasib in the neoadjuvant setting (before surgery) for resectable NSCLC (NCT05400577) [69] and in combination with novel agents like the SOS1 inhibitor BAY3498264 (NCT06659341).[70]
• Next-Generation Inhibitors: The broader scientific community is working to build upon the success of Sotorasib. This includes developing inhibitors against other common KRAS mutations, such as G12D (e.g., MRTX1133) and G12V.[71] Furthermore, novel approaches are being explored, such as pan-RAS inhibitors that target multiple KRAS mutants simultaneously, and RAS(on) inhibitors that target the active state of the protein, which could potentially overcome some forms of resistance to inactive-state inhibitors like Sotorasib.[71]

Table 6: Overview of Key Ongoing Clinical Trials for Sotorasib

Trial ID	Phase	Title/Objective	Combination Agents	Target Population/Indication
NCT04185883 (CodeBreaK 101) 43	1b	Basket trial to evaluate safety and efficacy of Sotorasib combinations	Multiple (e.g., Panitumumab, Pembrolizumab, Chemotherapy, SHP2 inhibitors)	Advanced Solid Tumors with KRAS G12C mutation
NCT05920356 (CodeBreaK 202) 68	3	Compare Sotorasib + Chemo vs. Pembrolizumab + Chemo in 1L	Platinum Doublet Chemotherapy	Stage IV or Advanced IIIB/C Nonsquamous NSCLC (PD-L1 negative, KRAS G12C+)
NCT04933695 (CodeBreaK 201) 73	2	Evaluate ORR of Sotorasib monotherapy in 1L	Monotherapy	Stage IV NSCLC (PD-L1 <1% and/or STK11 co-mutation, KRAS G12C+)
NCT05400577 69	N/A	Determine rate of major pathological response (MPR)	Monotherapy (Neoadjuvant)	Resectable Stage Ib-IIIA Non-squamous NSCLC with KRAS G12C mutation
NCT06659341 70	1	Evaluate safety and maximum tolerated dose of combination	BAY3498264 (SOS1 inhibitor)	Advanced Solid Cancers with KRAS G12C mutation

7. Expert Synthesis and Concluding Remarks

Sotorasib stands as a testament to decades of persistent scientific inquiry, representing the successful culmination of the quest to drug the KRAS oncogene. Its development and approval have fundamentally altered the therapeutic landscape for patients with KRAS G12C-mutated cancers, providing a targeted, oral therapy where previously only non-specific and more toxic options existed. The clinical data clearly establish its benefit in previously treated NSCLC, where it offers improved progression-free survival, higher response rates, and a superior quality of life compared to standard chemotherapy. In metastatic colorectal cancer, while ineffective as a monotherapy, its rational combination with an EGFR inhibitor has defined a new standard of care for a chemorefractory population.

However, the journey of Sotorasib also serves as a salient lesson in the complexities of modern oncology. The modest magnitude of its PFS benefit over chemotherapy in NSCLC and the inevitable and heterogeneous emergence of drug resistance underscore that inhibiting a single driver oncogene is often insufficient for durable disease control. The tumor's intrinsic biology, tissue-specific dependencies, and adaptive capabilities present formidable challenges that necessitate a more sophisticated, multi-pronged therapeutic approach.

The future of Sotorasib and, indeed, the entire field of KRAS inhibition, lies in the strategic implementation of combination therapies. The extensive CodeBreaK clinical program is appropriately focused on this next phase: identifying synergistic partners—be they chemotherapy, immunotherapy, or other targeted agents—to deepen responses, delay resistance, and move this therapeutic class into earlier lines of treatment where its impact can be greatest. Sotorasib has broken the barrier, proving that KRAS is a tractable target. It has laid the foundation upon which the next generation of more effective, durable, and potentially broader-acting KRAS-directed strategies will be built. Its legacy will be defined not only by its own success but by the new era of research and therapeutic innovation it has inspired.

Works cited

1. Sotorasib: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 6, 2025, [https://go.drugbank.com/drugs/DB15569]
2. AMG-510 (CAS 2252403-56-6) (ab287089) - Abcam, accessed August 6, 2025, [https://www.abcam.com/en\-us/products/biochemicals/amg\-510\-ab287089]
3. Sotorasib, a KRASG12C inhibitor for non-small cell lung cancer - PMC, accessed August 6, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9106916/]
4. Sotorasib | AMG-510 | CAS#2252403-56-6 | KRAS G12C inhibitor - MedKoo Biosciences, accessed August 6, 2025, [https://www.medkoo.com/products/33108]
5. 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(1-methylethyl)-3-pyridinyl]-4-[(2S - CAS Common Chemistry, accessed August 6, 2025, [https://commonchemistry.cas.org/detail?cas\_rn\=2252403\-56\-6]
6. Sotorasib, 2252403-56-6, SBR00089, Sigma-Aldrich, accessed August 6, 2025, [https://www.sigmaaldrich.com/US/en/product/sigma/sbr00089]
7. Compound: SOTORASIB (CHEMBL4535757) - ChEMBL - EMBL-EBI, accessed August 6, 2025, [https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL4535757]
8. CovalentInDB, accessed August 6, 2025, [http://cadd.zju.edu.cn/cidb/drug\_card/DB15569/]
9. AMG 510 | 2252403-56-6 - ChemicalBook, accessed August 6, 2025, [https://www.chemicalbook.com/ChemicalProductProperty\_EN\_CB24858719\.htm]
10. Sotorasib | C30H30F2N6O3 | CID 137278711 - PubChem, accessed August 6, 2025, [https://pubchem.ncbi.nlm.nih.gov/compound/Sotorasib]
11. Definition of sotorasib - NCI Drug Dictionary, accessed August 6, 2025, [https://www.cancer.gov/publications/dictionaries/cancer\-drug/def/sotorasib]
12. Sotorasib (oral route) - Side effects & dosage - Mayo Clinic, accessed August 6, 2025, [https://www.mayoclinic.org/drugs\-supplements/sotorasib\-oral\-route/description/drg\-20516741]
13. en.wikipedia.org, accessed August 6, 2025, [https://en.wikipedia.org/wiki/Sotorasib]
14. sotorasib | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed August 6, 2025, [https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId\=10678]
15. FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER - Amgen, accessed August 6, 2025, [https://www.amgen.com/newsroom/press\-releases/2025/01/fda\-approves\-lumakras\-sotorasib\-in\-combination\-with\-vectibix\-panitumumab\-for\-chemorefractory\-kras\-g12cmutated\-metastatic\-colorectal\-cancer]
16. Sotorasib Completed Phase 1 Trials for Healthy Volunteers (HV) Basic Science - DrugBank, accessed August 6, 2025, [https://go.drugbank.com/drugs/DB15569/clinical\_trials?conditions\=DBCOND0114743\&phase\=1\&purpose\=basic\_science\&status\=completed]
17. LUMAKRAS® (sotorasib): KRAS G12C-Mutated NSCLC Therapy, accessed August 6, 2025, [https://www.lumakrashcp.com/]
18. Learning from sotorasib: risk of bias in confirmatory clinical studies of accelerated approved drugs and resolution strategies - PubMed Central, accessed August 6, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11103877/]
19. FDA grants accelerated approval to sotorasib for KRAS G12C mutated NSCLC, accessed August 6, 2025, [https://www.fda.gov/drugs/resources\-information\-approved\-drugs/fda\-grants\-accelerated\-approval\-sotorasib\-kras\-g12c\-mutated\-nsclc]
20. Results From Phase 2 CodeBreaK 100 Show LUMAKRAS™ (sotorasib) Is The First And Only KRAS G12C Inhibitor With Overall Survival Data - Amgen, accessed August 6, 2025, [https://www.amgen.com/newsroom/press\-releases/2021/06/results\-from\-phase\-2\-codebreak\-100\-show\-lumakras\-sotorasib\-is\-the\-first\-and\-only\-kras\-g12c\-inhibitor\-with\-overall\-survival\-data]
21. CodeBreaK 100 Study Design - LUMAKRAS® (sotorasib), accessed August 6, 2025, [https://www.lumakrashcp.com/advanced\-non\-small\-cell\-lung\-cancer\-treatment\-efficacy]
22. CodeBreaK 100 Trial Results Demonstrate Sotorasib Conveys Clinical Benefit Across NSCLC Patient Subgroups, accessed August 6, 2025, [https://jhoponline.com/special\-issues/2021\-year\-in\-review\-non\-small\-cell\-lung\-cancer/codebreak\-100\-trial\-results\-demonstrate\-sotorasib\-conveys\-clinical\-benefit\-across\-nsclc\-patient\-subgroups]
23. CodeBreaK 100 Phase 2 Study Results Demonstrate Sotorasib Efficacy, accessed August 6, 2025, [https://www.jons\-online.com/special\-issues\-and\-supplements/2021/2021\-year\-in\-review\-non\-small\-cell\-lung\-cancer/codebreak\-100\-phase\-2\-study\-results\-demonstrate\-sotorasib\-efficacy]
24. Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100 | Journal of Clinical Oncology - ASCO Publications, accessed August 6, 2025, [https://ascopubs.org/doi/10\.1200/JCO.22\.02524]
25. Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100 - PubMed, accessed August 6, 2025, [https://pubmed.ncbi.nlm.nih.gov/37098232/]
26. Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). | ClinicalTrials.gov, accessed August 6, 2025, [https://clinicaltrials.gov/study/NCT04303780]
27. Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC). | Journal of Clinical Oncology - ASCO Publications, accessed August 6, 2025, [https://ascopubs.org/doi/10\.1200/JCO.2023\.41\.16\_suppl.9008]
28. CodeBreaK 200 Trial Sotorasib vs Docetaxel in Previously Treated Patients With Advanced KRAS G12C–Mutated NSCLC - The ASCO Post, accessed August 6, 2025, [https://ascopost.com/news/february\-2023/codebreak\-200\-trial\-sotorasib\-vs\-docetaxel\-in\-previously\-treated\-patients\-with\-advanced\-kras\-g12c\-mutated\-nsclc/]
29. FDA's ODAC Votes No for Sotorasib in KRAS G12C-Mutated NSCLC - Targeted Oncology, accessed August 6, 2025, [https://www.targetedonc.com/view/fda\-s\-odac\-votes\-no\-for\-sotorasib\-in\-kras\-g12c\-mutated\-nsclc]
30. CodeBreak 200: study limitations, and future directions - PMC - PubMed Central, accessed August 6, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10894345/]
31. Sotorasib improves PFS versus docetaxel in patients with pre-treated KRAS G12C-mutated NSCLC - ESMO Daily Reporter, accessed August 6, 2025, [https://dailyreporter.esmo.org/esmo\-congress\-2022/news/sotorasib\-improves\-pfs\-versus\-docetaxel\-in\-patients\-with\-pre\-treated\-kras\-g12c\-mutated\-nsclc]
32. Sotorasib Doubles PFS Rates vs Docetaxel in KRAS G12C–Mutated NSCLC, accessed August 6, 2025, [https://www.targetedonc.com/view/sotorasib\-doubles\-pfs\-rates\-vs\-docetaxel\-in\-kras\-g12c\-mutated\-nsclc]
33. Sotorasib Improves Progression-Free Survival vs Docetaxel in Previously Treated Advanced NSCLC With KRAS G12C Mutation - The ASCO Post, accessed August 6, 2025, [https://ascopost.com/issues/march\-25\-2023/sotorasib\-improves\-progression\-free\-survival\-vs\-docetaxel\-in\-previously\-treated\-advanced\-nsclc\-with\-kras\-g12c\-mutation/]
34. Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non–small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100. - ASCO Publications, accessed August 6, 2025, [https://ascopubs.org/doi/10\.1200/JCO.2022\.40\.16\_suppl.102]
35. FDA approves sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer, accessed August 6, 2025, [https://www.fda.gov/drugs/resources\-information\-approved\-drugs/fda\-approves\-sotorasib\-panitumumab\-kras\-g12c\-mutated\-colorectal\-cancer]
36. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C - PubMed, accessed August 6, 2025, [https://pubmed.ncbi.nlm.nih.gov/37870968/]
37. CodeBreaK 300: Sotorasib Plus Panitumumab of Benefit in KRAS-Mutated Metastatic Colorectal Cancer - The ASCO Post, accessed August 6, 2025, [https://ascopost.com/issues/december\-10\-2023/codebreak\-300\-sotorasib\-plus\-panitumumab\-of\-benefit\-in\-kras\-mutated\-metastatic\-colorectal\-cancer/]
38. The emerging role of Sotorasib plus Panitumumab combination therapy in colorectal cancer treatment - PubMed, accessed August 6, 2025, [https://pubmed.ncbi.nlm.nih.gov/40080361/]
39. Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer | Journal of Clinical Oncology - ASCO Publications, accessed August 6, 2025, [https://ascopubs.org/doi/10\.1200/JCO\-24\-02026]
40. Sotorasib at 960 mg Plus Panitumumab Emerges as SOC in KRAS G12C+ mCRC, accessed August 6, 2025, [https://www.cancernetwork.com/view/sotorasib\-at\-960\-mg\-plus\-panitumumab\-emerges\-as\-soc\-in\-kras\-g12c\-mcrc]
41. Overall survival (OS) of phase 3 CodeBreaK 300 study of sotorasib plus panitumumab (soto+pani) versus investigator's choice of therapy for KRAS G12C-mutated metastatic colorectal cancer (mCRC). - ASCO Publications, accessed August 6, 2025, [https://ascopubs.org/doi/10\.1200/JCO.2024\.42\.17\_suppl.LBA3510]
42. Sotorasib Active Not Recruiting Phase 2 Trials for Efficacy Treatment | DrugBank Online, accessed August 6, 2025, [https://go.drugbank.com/drugs/DB15569/clinical\_trials?conditions\=DBCOND0037571\&phase\=2\&purpose\=treatment\&status\=active\_not\_recruiting]
43. Study Details | Sotorasib Activity in Subjects With Advanced Solid ..., accessed August 6, 2025, [https://www.clinicaltrials.gov/study/NCT04185883]
44. Pancreatic Cancers Withdrawn Phase 1 / 2 Trials for Sotorasib (DB15569) - DrugBank, accessed August 6, 2025, [https://go.drugbank.com/indications/DBCOND0072930/clinical\_trials/DB15569?phase\=1%2C2\&status\=withdrawn]
45. This label may not be the latest approved by FDA. For current ..., accessed August 6, 2025, [https://www.accessdata.fda.gov/drugsatfda\_docs/label/2023/214665s004lbl.pdf]
46. LUMAKRAS® (sotorasib): NSCLC and mCRC Treatment, accessed August 6, 2025, [https://www.lumakras.com/]
47. LUMAKRAS-Patient-Brochure-Digital-English.pdf, accessed August 6, 2025, [https://www.lumakras.com/resources/\-/media/Themes/Amgen/lumakras/lumakras/pdf/LUMAKRAS\-Patient\-Brochure\-Digital\-English.pdf]
48. Lumakras (sotorasib) dosing, indications, interactions, adverse effects, and more, accessed August 6, 2025, [https://reference.medscape.com/drug/lumakras\-sotorasib\-4000155]
49. Taking LUMAKRAS® for NSCLC with KRAS G12C, accessed August 6, 2025, [https://www.lumakras.com/nsclc/about\-lumakras/taking\-lumakras]
50. Union Register of medicinal products - Public health - European Commission, accessed August 6, 2025, [https://ec.europa.eu/health/documents/community\-register/html/h1603\.htm]
51. Lumykras | European Medicines Agency (EMA), accessed August 6, 2025, [https://www.ema.europa.eu/en/medicines/human/EPAR/lumykras]
52. Sotorasib| European Medicines Agency - PharmGKB, accessed August 6, 2025, [https://www.pharmgkb.org/literature/15132884]
53. EUROPEAN COMMISSION APPROVES LUMYKRAS® (SOTORASIB) FOR PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER - Amgen, accessed August 6, 2025, [https://www.amgen.com/newsroom/press\-releases/2022/01/european\-commission\-approves\-lumykras\-sotorasib\-for\-patients\-with\-kras\-g12cmutated\-advanced\-nonsmall\-cell\-lung\-cancer]
54. LUMYKRAS (sotorasib) Receives Positive Opinion From EMA CHMP For Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer - FirstWord Pharma, accessed August 6, 2025, [https://firstwordpharma.com/story/5441169]
55. LUMAKRAS® (sotorasib) Dosing | Oral KRAS G12C Inhibitor, accessed August 6, 2025, [https://www.lumakrashcp.com/sotorasib\-dosing]
56. Mechanisms of resistance to KRASG12C inhibitors in KRASG12C ..., accessed August 6, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11410594/]
57. Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer - Frontiers, accessed August 6, 2025, [https://www.frontiersin.org/journals/oncology/articles/10\.3389/fonc.2021\.787585/full]
58. Overcoming amplification-mediated resistance to sotorasib by dose re-escalation in KRAS G12C mutant NSCLC: a case report | The Oncologist | Oxford Academic, accessed August 6, 2025, [https://academic.oup.com/oncolo/article/30/3/oyaf030/8087943]
59. Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non–small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100. - ResearchGate, accessed August 6, 2025, [https://www.researchgate.net/publication/361122909\_Largest\_evaluation\_of\_acquired\_resistance\_to\_sotorasib\_in\_KRAS\_pG12C\-mutated\_non\-small\_cell\_lung\_cancer\_NSCLC\_and\_colorectal\_cancer\_CRC\_Plasma\_biomarker\_analysis\_of\_CodeBreaK100]
60. Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation - PubMed, accessed August 6, 2025, [https://pubmed.ncbi.nlm.nih.gov/40542959/]
61. (PDF) Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation - ResearchGate, accessed August 6, 2025, [https://www.researchgate.net/publication/392903609\_Matching\-Adjusted\_Indirect\_Comparison\_of\_Sotorasib\_Versus\_Adagrasib\_in\_Previously\_Treated\_AdvancedMetastatic\_Non\-Small\_Cell\_Lung\_Cancer\_Harboring\_KRAS\_G12C\_Mutation]
62. KRAS Inhibitors Show Efficacy in Randomized NSCLC Trials - Targeted Oncology, accessed August 6, 2025, [https://www.targetedonc.com/view/kras\-inhibitors\-show\-efficacy\-in\-randomized\-nsclc\-trials]
63. What's the difference between Sotorasib and Adagrasib? A simple overview. - Everyone.org, accessed August 6, 2025, [https://everyone.org/blog/difference\-between\-sotorasib\-and\-adagrasib]
64. Clinical Trials Show Efficacy of Adagrasib in Patients with NSCLC and Brain Metastases, accessed August 6, 2025, [https://www.theoncologynurse.com/lung\-cancer\-mm/clinical\-trials\-show\-efficacy\-of\-adagrasib\-in\-patients\-with\-nsclc\-and\-brain\-metastases]
65. Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRAS G12C -Mutated Non–Small Cell Lung Cancer: A Case Series and Literature Review - ASCO Publications, accessed August 6, 2025, [https://ascopubs.org/doi/10\.1200/PO.23\.00644]
66. FDA Grants Sotorasib Priority Review Designation For The Treatment Of Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer - Amgen, accessed August 6, 2025, [https://www.amgen.com/newsroom/press\-releases/2021/02/fda\-grants\-sotorasib\-priority\-review\-designation\-for\-the\-treatment\-of\-patients\-with\-kras\-g12c\-mutated\-locally\-advanced\-or\-metastatic\-non\-small\-cell\-lung\-cancer]
67. Data Look Promising for First-line Sotorasib, Platinum-based Chemotherapy Combination for KRAS-mutant NSCLC, accessed August 6, 2025, [https://www.ilcn.org/data\-look\-promising\-for\-first\-line\-sotorasib\-platinum\-based\-chemotherapy\-combination\-for\-kras\-mutant\-nsclc/]
68. Study Details | A Study Evaluating Sotorasib Platinum Doublet ..., accessed August 6, 2025, [https://clinicaltrials.gov/study/NCT05920356]
69. Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC | ClinicalTrials.gov, accessed August 6, 2025, [https://www.clinicaltrials.gov/study/NCT05400577]
70. A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation | ClinicalTrials.gov, accessed August 6, 2025, [https://clinicaltrials.gov/study/NCT06659341?cond\=(NOONAN%20SYNDROME)%20OR%20(SOS1\)\&rank\=3]
71. The Future of KRAS Targeting Cancer Therapies Beyond G12C - DelveInsight, accessed August 6, 2025, [https://www.delveinsight.com/blog/kras\-inhibitors\-beyond\-g12c]
72. The next generation of KRAS targeting: reasons for excitement and ..., accessed August 6, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9633538/]
73. A Study of Sotorasib (AMG 510) in Participants ... - ClinicalTrials.gov, accessed August 6, 2025, [https://clinicaltrials.gov/study/NCT04933695]